NCT05706454 - Phase 2/Phase 3 Study To Evaluate The Efficacy And Safety Of Ramatroban Along With The Standard Of Care In Subjects Hospitalized For COVID Pneumonia | Biotech Hunter

Enrollment

324

Participants

Timeline

Start Date

November 10, 2022

Primary Completion Date

July 1, 2024

Study Completion Date

May 31, 2026

Conditions

COVID-19 PneumoniaCOVID-19 Respiratory Infection

Interventions

DRUG

Ramatroban

"Route of Administration: Oral Dose: 75 mg; Frequency: Twice daily; Total duration of intervention: 28 days.~Subjects will be evaluated over a study period of approximately 365 days."

DRUG

Placebo

Matching placebo will be administered orally twice a day

Trial Locations (7)

382405

RECRUITING

Shakti Superspecialty Hospital, Ahmedabad

411027

RECRUITING

Sangvi Multispecialty Hospital Pvt Ltd, Pune

411033

RECRUITING

Saikrupa Hospital, Pune

RECRUITING

Spandan Hospital, Pune

411044

RECRUITING

PDEA'S Ayurved Rugnalaya & Sterling Multispeciality Hospital, Pune

524001

RECRUITING

DEC Health Care, Nellore

400028,

RECRUITING

Lifecare Hospital, Mumbai